Studies have shown that DLX6-AS1 contributes to tumor progression by enhancing cell proliferation, migration, invasion, and epithelial–mesenchymal transition (EMT) while simultaneously suppressing apoptosis in cancer cells (reviewed by Ghafouri-Fard et al., 2022 [116]). Here, DLX6 is linked to neoplasm.